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Abstract
Background: During the last decade, pathology services in England have undergone profound changes with an
extensive consolidation of laboratories. This has been driven by some national reviews forecasting a national
reduction of costs by £250–£500 million ($315–$630 million) a year as a result.
The main aim of this paper is to describe the financial impact of such consolidation, with a specific focus on the
forecasted savings. A secondary aim is to describe the development of private sector involvement in laboratory
services in a traditionally publicly funded healthcare system and the development of pathology staff size.
Methods: In the English scenario, the majority of hospitals and laboratories are publicly funded and a survey was
sent as Freedom of Information request to all directors of pathology. A descriptive comparison of savings among
consolidated and non-consolidated pathology services was made by using the pathology budgets in two different
periods (2015 versus 2010), adjusted by inflation and increased activity.
Results: The hub-and-spoke model has been implemented as part of the consolidation process of pathology
services in England. Consolidated pathology networks have achieved higher savings compared to non-
consolidated single laboratories. There has been an increased role of private providers and savings were
achieved with negligible personnel redundancies.
Conclusions: Consolidated units have on average achieved larger cost savings than non-consolidated units
but further analysis with stronger research design is required to independently evaluate the impact of pathology
consolidation on both savings and quality.
Keywords: Consolidation of pathology services, Savings, England
Background
Pathology services are an essential component of any
healthcare system as they provide all laboratory tests for
any patient in and out the hospital settings. They are
represented by the main specialities of clinical biochem-
istry, haematology, blood transfusion, microbiology and
histopathology.
Different countries around the globe have undergone
consolidation of their pathology services in an attempt to
reduce costs, meet increasing demand and achieve effi-
ciency savings whilst modernizing laboratory infrastruc-
ture with new technologies. However, there is a paucity of
published data regarding the effects of merging pathology
laboratories, in particular the financial benefits following a
wider national policy of consolidation. Most of the current
evidence in healthcare is based on the benefits of merging
entire hospitals. Classical examples include the Mayo and
Cleveland clinics in the United States (US) [1, 2]: they
have grown through mergers to become some of the most
highly regarded hospital systems in the world. More
recent evidence from a large sample of US hospital
mergers between 2000 and 2010 found evidence of eco-
nomically and statistically significant cost reductions at ac-
quired hospitals [3]. University College London Hospitals
(UCLH), created in 2004 from the merger of six different
hospitals, is the best example in the United Kingdom
(UK) [4]. UCLH has achieved a strong market share in
several key specialties. It scores highly in national rankings
of care quality and patient satisfaction and has sustained
robust financial performance. However, these examples
may not directly translate to pathology services as
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previous reports [5, 6] suggest that the cost savings
achieved are typically in back-office and from the reduc-
tion of management functions rather than clinical costs,
whilst savings in the pathology sector may results from
the economy of scale and higher purchase discounts.
These examples may also represent isolated success stories
as an earlier analysis of more than 700 US hospital
mergers by McKinsey and the London School of Econom-
ics [7] found that the cost savings achieved were substan-
tially less than the original anticipated benefits. Similar
findings from the analysis of more than 100 UK hospital
mergers [8] have found that in many sites clinical product-
ivity remained unchanged and the financial performance
deteriorated, with none of them enhancing the quality of
care. This is also confirmed by a report from Norway [9]
where they discovered that only one hospital out of 17
actually increased its cost efficiency.
Consolidation of pathology services in US
There are some successful examples of laboratory consoli-
dation from the US [10]. The decline of the reimburse-
ment rate since 1980 and cuts under the Clinical
Laboratory Fee Schedule (CLFS) have had a profound im-
pact on US laboratories, making pathology services less
profitable and forcing many providers to merge. Between
2010 and 2013, CLFS reimbursement rates were effectively
cut by nearly 12% [11]. A recent paper on the consolida-
tion of clinical microbiology laboratories [12] highlights
how, in the state of North Carolina (with a total popula-
tion of around 10 million), five hospital systems dominate
the health care landscape, with catchment areas exceeding
hundreds of miles. The main core microbiology laboratory
covers up to 40 different hospitals and its consolidation
has achieved decreased turn-around-times (TATs) and
reductions of costs, as a consequence of discount when
purchasing in high volume. Conversely, earlier evidence
suggested that TATs can be a major issue in the consoli-
dated model [13], so the impact of consolidating labora-
tories on patient care still needs to be evaluated.
Consolidation of pathology services in Australia
An interesting report from the Grattan Institute, a pub-
lic policy think tank, [14], has highlighted impressive
efficiency savings with the consolidation of Australian
pathology services, and with two private providers
dominating the market. However, this privatization has
not been exempted from criticism, with accusation of
not re-investing such savings into the public healthcare
system and suggesting the government to introduce
price competition into the market.
Consolidation of pathology services in Europe
The best example of consolidation of pathology services
in Europe is represented by Germany. Around 15 years
ago, Germany had approximately 800 pathology labora-
tories, most of which were publicly funded [15]. Due to
running costs of the services, since 1991 radical reforms
of the system have seen bed capacity fall by almost a
fifth and the number of hospitals by 9% [16] (including a
35% reduction in the number of pathology laboratories)
and the German system has achieved a progressive
reduction of tariffs equivalent to circa 40% of English
reference costs for similar tests. This was also possible
due to the fact that the tariff for pathology services is ac-
tually fixed, so the various providers can only compete
on quality of service and clinical advice, rather than
costs. The pathology landscape in Germany is now very
different, with the majority of District General Hospitals
(DGH) only equipped with a core laboratory for urgent
testing (i.e. result needed in less than 2 h) and scientists
cross trained in all pathology specialties. The majority of
these core laboratories are part of wider pathology net-
works (largely privatized) and with the predominance of
five private providers covering up to 60% of the German
pathology market.
Consolidation of pathology services in England
The National Health Service (NHS) is the publicly
funded national healthcare system in England and the
biggest of the four National Health Services of the
UK, catering to a population of 54.3 million and
employing around 1.2 million people. It is the largest
single-payer healthcare system in the world with the
majority of services completely free at the point of
use and with an overall budget of £101.3 billion
(around $128 billion) (NHS England data for 2015/
16) [17]. Please note that similar healthcare systems
are available in Scotland, Wales and Northern Ireland.
During the last decade, pathology services in England
have undergone profound changes. In particular, the
Carter review [18] was published in 2006 and it
highlighted the importance of pathology services (with
an estimated 70–80% of all healthcare decisions
affecting diagnosis or treatment being influenced by
laboratory medicine results) but also its high cost
(£2.5–$3.15 billion per annum). It also showed a wide
variation of prices across the country for the same
identical tests (but performed in different
laboratories) with uncontrolled budgeting and rising
costs. The solution proposed was a large-scale service
consolidation of different laboratories with possible
savings of £4–5 million ($5–6.3 million) by one net-
work only (in England, there were around 150 hospi-
tals offering pathology services). A second review,
following various pilot projects, was published in
2010 [19] and it confirmed the strong case for con-
solidation of pathology services to improve quality,
patient safety and efficiency, with a hub-and-spoke
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model (a central hub, where the majority of
non-urgent tests can be performed, and district
spokes, to process urgent specimens). Of note, in the
foreword of this document, a total national reduction
of costs by £250–£500 million ($315–£630 million) a
year was forecasted as a result of consolidation.
Hence, the main aim of this paper is to compare the de-
velopment of costs in consolidated and non-consolidated
units in England, in particular assessing the achievement
of the forecasted savings. A secondary aim is the descrip-
tion of private sector involvement in a traditionally
publicly funded healthcare system and the impact on
pathology staff in terms of personnel size and
redundancies.
Methods
A survey was sent as a Freedom of Information (FOI) re-
quest to all directors of pathology laboratories in English
NHS hospitals. The FOI (based on the Freedom of Infor-
mation Act 2000) allows any citizen to access information
held by public authorities (in the English scenario, the
majority of hospitals are publicly funded). A FOI request
was chosen as the best method to obtain the necessary in-
formation. This was a reasoned decision with two main
considerations in mind: it would have been very difficult to
find the contact details of all directors of pathology in Eng-
land and the response rate would have been affected and
much lower.
Selection of NHS hospitals and data collection
The survey focused on pathology services in two separate
periods, 2010 and 2015, collecting information on the
presence of laboratories on site, the total pathology
budget, consolidation (existing or planned), the role of pri-
vate providers (if any), and the number of staff (including
redundancies).
The original list included all acute NHS hospitals in
England and it was taken from the NHS Choice web-
site [20]. Mental health hospitals and community pro-
viders were excluded as they do not have their own
pathology services. Historically, the majority of hospi-
tals used to have their own laboratory and pathology
services on site. To avoid missing important informa-
tion and taking into consideration all the recent
changes and mergers in the NHS scenario, the FOI
included a specific question on how many hospitals
the NHS organization (also called NHS Trust/Founda-
tion Trust) were currently managing and if those hos-
pitals used to have separate pathology services in the
year 2010. The original list included 160 names but it
has been reduced to 153 as two mental health hospi-
tals were excluded and five other NHS Trusts did not
exist anymore (acquired or merged with another).
Please note that NHS Trusts/Foundation Trusts may
include different hospitals as part of their network.
Analysis of data
A descriptive calculation of savings among consoli-
dated and non-consolidated pathology services was
made by comparing two different periods (2015 ver-
sus 2010). However, a direct comparison of the two
budgets would have not been reasonable as the infla-
tion and increased activity should also be taken into
consideration. The 2010 budget was then adjusted
using the inflation calculator provided by the Bank of
England (inflation averaged 3.0% a year) [21]. Based
on The King’s Fund data, the NHS has constantly in-
creased its activity in the last decade [22]. A conser-
vative assumption was made that during those 5 years
there was an increased laboratory activity of 10% and
such percentage of the 2015 budget was added when
calculating savings. A statistical significance using the
t-test was performed to compare the average savings.
Additionally, a relative comparison based on the total
savings divided by the size of the laboratories (num-
ber of personnel) has also been performed to aug-
ment the analysis and validate the statistical
significance.
Results
Response rate and missing data
Complete information was obtained for 135 out of 153
(88%) organizations. Incomplete information was obtained
for 18 organizations as fifteen NHS Trusts/Foundation
Trusts were unable to provide the information for both
periods and three organizations did not respond to the
FOI request. However, they were still included in the ini-
tial epidemiological analysis but not in the budget
comparison.
Number of centralized laboratories in 2010 and 2015
(n = 153)
At the time of the FOI request (end of 2016), the
majority of Trusts in England (n = 89–58.2% of the
total) had already gone through a process of consoli-
dating their pathology services. Many of these Trusts
now cover different hospitals (i.e. Imperial Healthcare
includes St Mary’s, Hammersmith and Charing Cross
Hospitals, all of which used to have their own separ-
ate pathology laboratories) and many of them share
their pathology services with neighbouring partners
(i.e., North West London Pathology covers Imperial
Healthcare, Chelsea and Westminster and the Hilling-
don hospitals). However, there is still a significant
number of Trusts (n = 61–39.8% of the total) that
have not yet had any consolidation of their pathology
services. Around half of them (n = 27–17.6% of the
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total) are planning a consolidation of their pathology
services in the near future (Fig. 1).
Comparison of consolidated versus non-consolidated
laboratories (n = 135)
Complete information was obtained for 135 NHS
Trusts (but covered by 113 laboratories), 78 with con-
solidated pathology services and 57 with independent
single laboratories. Those 78 organizations had con-
solidated their laboratory services into 56 pathology
hubs, with an average size of 278 employees per hub
(total number: 15,550). On the other hand, the 57
single laboratories have an average size of 155 em-
ployees per laboratory (total number: 8835). The
budget information is shown in Table 1:
– There would be no cost savings at all in both
consolidated and non-consolidated laboratories by
simply comparing the total budgets 2010 versus
2015. The total national budget for 2015 is higher
than the 2010 budget.
– However, after adjusting the 2010 budget for
inflation, it is possible to calculate total national
savings (if any) by detracting the 2015 budget.
The 56 pathology hubs (consolidated laboratories)
have saved £76,717,848. On the other hand, the
non-consolidated laboratories have not made any
savings and lost £825,471.
– When including the increased activity (10% of
2015 budget), the combined consolidated
laboratories have saved £188,191,500 compared to
£73,065,515 of non-consolidated laboratories.
– When calculating the average saving per
laboratory, consolidated hubs have saved
£3,360,562 each, whilst non-consolidated labora-
tories have saved £1,281,851 each. This difference
is statistically significant (p = 0.0003).
– When calculating the relative saving per member
of staff, consolidated hubs have saved £12,102 per
Fig. 1 Centralization of laboratories in England. The majority of laboratory in England are already consolidated (n = 89 out of a total of 153).
Around half of the remaining non-consolidated laboratories (n = 27) are planning a consolidation in the near future
Table 1 Comparison of total budgets: 2010, with and without inflation, versus 2015
Consolidated laboratories
(n = 56 pathology hubs)
Non-consolidated laboratories
(n = 57 single laboratories)
Total budget
2010
Total budget
2015
Total budget 2010
with inflation
Difference
(savings or deficit)
Total budget
2010
Total budget 2015 Total budget 2010
with inflation
Difference
(savings or deficit)
£1,030,140,845 £1,114,736,579 £1,191,454,427 £76,717,848 (savings) £631,153,715 £738,909,949 £738,084,478 -£825,471 (deficit)
Value of 10% increased activity: £111,473,652 Value of 10% increased activity: £73,890,986
Total savings including increased activity:
£188,191,500
Total savings including increased activity:
£73,065,515
Average savings per pathology hub Average savings per single laboratory
£3,360,562 (SD: £3,672,787) £1,281,851 (SD: £2,074,070)
p = 0.0003
Average size of pathology hub (number of staff): 278 Average size of single laboratory (number of staff): 155
Relative saving per member of staff: Relative saving per member of staff:
£12,102 (SD: £236) £8270 (SD: £235)
p = 0.0001
Savings (total, average and per employee) and size of consolidated laboratories versus non-consolidated are also shown. All sums are in British sterling (£).
SD = standard deviation. Not all laboratories have achieved savings and this explains the wide standard deviation observed in both groups
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employee versus £8270 per employee in a non-
consolidated laboratory. This difference is again
statistically significant (p = 0.0001).
It is important to notice that not all laboratories in both
groups (consolidated and non-consolidated) have made sav-
ings. Whilst some laboratories have achieved high savings in
their budget, others have experienced significant losses. In
particular, five consolidated and fifteen non-consolidated la-
boratories have recorded a deficit in their budget. A graph-
ical comparison of savings and deficits is shown in Fig. 2.
Number and share of private providers
There was a minimal role for the private sector in the NHS
pathology market in 2010. At the time, only one hospital
used a private provider for its pathology services and all
other laboratories were public. However, the figures are dif-
ferent when comparing the data for 2015. A number of hos-
pitals (14 = 9% of the total, half of which are in London) are
now partially managed by a private provider. A joint venture
(between private and NHS) is present in 10 Trusts, whilst
the other 4 Trusts have completely outsourced their path-
ology services. The total value for these pathology services is
£237,223,655, equivalent to 13% of the total national path-
ology budget (Fig. 3).
Impact on pathology staff
The total number of the pathology workforce in England
is estimated to be 28,886 people (including all original
153 organizations), with various levels of experience
from laboratory assistants to medical consultants. As a
consequence of consolidation, 41 organizations (27% of
the total) had to make some redundancies as part of
their service reconfiguration. Nationwide, there have
been 189 redundancies in the last 5 years, equivalent to
0.7% of the total workforce. Additionally, 46 Trusts
(31%) have TUPE (transfer of undertakings) transferred
their pathology staff, and this has affected 7451 people
(26% of the total pathology workforce) (Fig. 4). The
TUPE transfer can have an impact on pension contribu-
tion, in particular if personnel are transferred to a pri-
vate provider. Only NHS staff is allowed to be part of
the generous NHS pension scheme and transfer to
another provider may cause a reduction in the final
benefits.
Discussion
The hub-and-spoke model has been implemented as part
of the consolidation process of pathology services in
England. Our analysis seems to confirm some of the an-
nual national savings forecasted by the Carter’s reviews,
but only when taking into consideration inflation and in-
creased activity. Further analysis with stronger research
design is required to confirm the role of consolidating
laboratories in achieving financial savings. This acquires
even more importance in view of the new push for path-
ology consolidation in England: new pathology networks
have been identified by NHS improvement and these are
Fig. 2 Consolidated versus non-consolidated laboratories. Graphical comparison of savings and deficits in consolidated (n= 56) versus non-consolidated
(n= 57) laboratories. Each dot represents a laboratory (hub or single). Not all laboratories have achieved savings and this explains the negative values
above (values under the red line). The two black lines indicate the mean or average savings per laboratory
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expected to save the NHS at least £200 million pounds
by 2020–2021 [23]. Previous Carter’s reviews [18, 19]
also made a strong case supporting the consolidation of
pathology services to improve quality and patient safety.
However, the impact on quality and patient safety still
need to be demonstrated. The lack of pathology tariffs is
an anomaly in the NHS funding streams. Examples from
the US and Europe have demonstrated how the reduc-
tion of the reimbursement rate (or tariff ) was one of the
major drivers in shaping the consolidation and this
could explain the slow pace of change that has affected
pathology services in England. Also, the introduction of
tariffs could potentially increase quality. A fixed national
tariff can be eventually reduced to drive efficiency sav-
ings but, at the same time, the various providers would
only compete on quality of service and clinical advice,
rather than costs.
The consolidation of pathology services has been par-
alleled by an increase in private sector involvement, now
reaching 13% of the total pathology budget. This is
mostly due to the lack of funds of many NHS hospitals
and the initial capital investment necessary for the con-
solidation process. The interest of private sector in pro-
viding pathology services should not come as a surprise.
The total pathology budget is worth more than 2 billion
pounds and there is a wide range of technology and
diagnostic companies that would like a share of it. How-
ever, this involvement is still limited when compared to
other countries, in particular USA, Australia and
Germany. Further analysis is needed to assess the role of
private providers in the English NHS, in terms of advan-
tages and disadvantages.
It has already been mentioned that savings in path-
ology generally result from the economy of scale and
higher purchase discounts. Our analysis shows that the
impact of consolidation on pathology staff has been
minimal in terms of redundancies, with only 0.7% being
affected. However, a fourth of the total workforce has
been transferred to another organization, with potential
changes in contract conditions and pension contribu-
tions. Data from telecommunication industries [24] have
shown that mergers can decrease the workforce morale,
affect the overall productivity (with low work perform-
ance and increased errors) and the relationships among
co-workers. Unfortunately, there have been no studies
on the impact of laboratory consolidation on the reten-
tion of specialized staff and the quality of pathology
services. This was outside the remit of this project but it
is a potential issue that would be worth further
investigation.
Finally, it is important to consider the limitations of
our study. The consolidation of pathology services in
England is a dynamic and complex event, involving hun-
dreds of laboratories and an evolving process. A direct
comparison like-for-like may not always be possible due
to recent mergers and closure of some laboratories. We
have performed a simple descriptive comparison of path-
ology budgets in two different periods (2010 versus
2015) to reflect the majority of consolidations and, inev-
itably, some assumptions were made (inflation and
increased activity). Such calculation did not consider the
national cost improvement targets and it does not actu-
ally demonstrate the direct link between consolidation of
pathology services and savings. This is to provide the
reader with the actual data with minimal manipulation
Fig. 4 Impact of consolidation of laboratory services on pathology staff. In the last 5 years, there has been a minimal number of redundancies
(0.7%) but 25.8% of staff have been TUPE transferred to a new organization
Fig. 3 Role of Private providers. Data provided for 2015 show an
increased role of private providers (bottom line), now equivalent to
13% of the total pathology budget
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and the overall picture of the national pathology budget
in relation to the forecasted savings proposed in the ori-
ginal Carter’s review. With this in mind, we would wel-
come debate and further analysis to independently
evaluate the impact of pathology consolidation on both
savings and quality.
Conclusion
Consolidated units have on average achieved larger cost
savings than non-consolidated units’, but there is a small
minority of providers that have actually experienced a
deficit, even when taking into consideration inflation
and increased activity. In addition, the consolidation of
services has opened the pathology market to the private
sector, with an increased number of private laboratories
operating in the last 5 years. Our analysis is unable to
directly prove that the greater cost savings are due to
the consolidation process but savings were achieved with
negligible redundancies. The long-term impact on the
pathology workforce and the quality of pathology ser-
vices is worth further investigation.
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